Updated:
Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is a biotech led by Douglas Onsi, developing DKK1-targeted therapies for esophagogastric, gynecologic, and colorectal...
Leap Therapeutics
Leap Therapeutics is a publicly traded biotechnology company focused on targeted cancer therapies. Douglas Onsi became President & CEO in April 2020; he joined the firm in 2011 as CFO. The company was previously led by Christopher Mirabelli, who remains Chairman and is a managing director at HealthCare Ventures. Leap's core asset is sirexatamab (DKN-01), a monoclonal antibody targeting the DKK1 protein. It is being studied in esophagogastric, gynecologic, and colorectal cancers. The pipeline also includes FL-301, a Claudin18.2 antibody in development for gastric and pancreatic cancer, and FL-501, a GDF-15 inhibitor in preclinical stages. The company operates from a single Cambridge, MA office. The firm does not disclose AUM or team size. Its board includes directors from healthcare venture capital, investment firms, and biopharma. Directors include Christian Richard — healthcare portfolio manager at Monashee Investment Advisors — and Will McEvoy, a principal at Winklevoss Capital since 2022. Leap's structural differentiator is its focus on a single well-validated target — DKK1 — across multiple tumor types, using a humanized monoclonal antibody approach. This narrow mandate contrasts with broader biotech platforms, concentrating clinical risk on the DKN-01 program.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
47 Thorndike St, Suite B1-1, Cambridge, MA, 02141, United States
Principals
Douglas Onsi
President & CEO
Christopher Mirabelli
Chairman of the Board of Directors
Khing Oei
Director
Will McEvoy
Director
James Cavanaugh
Director
Thomas Dietz
Director
William Li
Director
Joseph Loscalzo
Director
Nissim Mashiach
Director
Patricia Martin
Director
Christian Richard
Director
Richard L. Schilsky
Director
Sector focus
Frequently asked questions
Who runs investment decisions at Leap Therapeutics?
Douglas Onsi serves as President and CEO, responsible for corporate strategy and pipeline development. The board of directors includes members from venture capital and investment firms, providing oversight.
What is Leap Therapeutics' lead drug candidate?
Sirexatamab (DKN-01) is a humanized monoclonal antibody targeting the DKK1 protein, in clinical development for esophagogastric, gynecologic, and colorectal cancers.
How does Leap Therapeutics source its drug targets?
Leap in-licenses or internally discovers antibodies against well-validated cancer targets. DKN-01 targets DKK1, FL-301 targets Claudin18.2, and FL-501 targets GDF-15. The company does not disclose specific licensing partners.
Is Leap Therapeutics a family office or a biotech company?
Leap Therapeutics is a publicly traded biotechnology company (Nasdaq: LPTX). It is not structured as a family office.
What investment stages does Leap Therapeutics target?
Leap is a clinical-stage biotech developing early-to-mid-phase oncology assets. It invests internal resources in its own pipeline, not external deals.
Does Leap Therapeutics invest in other companies?
No. Leap focuses entirely on advancing its own drug candidates and does not function as an investment vehicle for external firms.
Where does Leap Therapeutics' founding wealth come from?
Leap Therapeutics was founded as a venture-backed biotech. Its early investors included HealthCare Ventures, where Chairman Christopher Mirabelli is a managing director. The specific founding wealth origin is not publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: